Quick Summary
- Johnson & Johnson delivered Q2 adjusted earnings per share of $2.90, surpassing the analyst consensus of $2.85
- Quarterly revenue reached $25.31 billion, representing 6.6% year-over-year growth and exceeding Wall Street projections
- The company elevated its annual revenue forecast to approximately $101.1 billion; adjusted EPS outlook increased to $11.68 midpoint
- Tremfya revenue jumped 72.5% to reach $2 billion; Darzalex generated $4.2 billion in sales
- Shares of JNJ declined approximately 2% during premarket hours despite the positive results and upgraded guidance
Johnson & Johnson delivered second-quarter financial results that exceeded analyst projections, yet the healthcare giant’s shares retreated in early trading. The stock dropped about 2% in Wednesday’s premarket session, despite management elevating its full-year financial targets.
The company posted adjusted earnings per share of $2.90, comfortably beating the Street’s $2.85 expectation. Revenue totaled $25.31 billion, marking a 6.6% increase compared to the prior-year period and topping the $25.05 billion consensus forecast.
The muted investor response makes sense in context. Shares of J&J had already climbed nearly 23% year-to-date through the earnings release, significantly outperforming the S&P 500’s 10% advance. A solid but not spectacular earnings performance wasn’t likely to fuel additional momentum.
The pharmaceutical segment delivered the strongest performance. This division generated $16.38 billion in quarterly revenue, surpassing analyst expectations of $16.1 billion.
Tremfya emerged as a major bright spot. The treatment for psoriasis and inflammatory bowel conditions recorded $2 billion in revenue, soaring 72.5% versus the same quarter last year and significantly exceeding LSEG projections of $1.74 billion. Tremfya’s performance grows increasingly critical as J&J navigates the revenue decline from Stelara, which has faced substantial erosion since biosimilar alternatives entered the market in 2025.
Darzalex, the company’s blood cancer therapy, generated $4.2 billion in revenue, meeting analyst forecasts. Additional contributions from Carvykti and Tecvayli helped propel 6.8% expansion in the Innovative Medicine oncology division.
MedTech Underperforms, Impella Concerns Surface
The MedTech segment represented the quarter’s disappointment. Revenue totaled $8.93 billion, reflecting 4.5% growth but missing the $9 billion Wall Street projection.
Impella heart pump revenue within MedTech declined 2% year-over-year. This marks a dramatic shift from the 14% expansion recorded in the first quarter. CFO Joseph Wolk pointed to a U.K. research study released earlier this year that questioned Impella’s effectiveness in specific high-risk coronary interventions.
Wolk indicated J&J anticipates the product category will resume growth as additional supporting evidence becomes available. “We have a big data set coming out probably in the first half of next year that should allay any fears,” he stated.
Full-Year Outlook Upgraded
J&J increased its annual financial projections across both key metrics. Management now projects revenue of roughly $101.1 billion at the midpoint, up from the previous $100.8 billion estimate. The adjusted EPS forecast rose to $11.68 at midpoint, compared to the prior $11.55 guidance.
Wells Fargo analyst Lawrence Biegelsen had observed before the earnings announcement that J&J had elevated its revenue guidance during a second-quarter report just once over the past four years, suggesting this could serve as a positive indicator.
J.P. Morgan analyst Chris Schott characterized J&J as “one of the cleaner names” among its competitive set as the company transitions beyond the Stelara patent expiration.
According to Wolk, J&J now operates 28 distinct platforms that each produce at least $1 billion in annual revenue.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
